ConductScience.org, home
A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma
API referenceFor AI assistants

Trial · NCT02594384

Results by group137

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 137

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Determination of the Maximum Tolerated Dose (MTD) of Continuous Oral LAM-002AAll Participants125mg BID
Peak Plasma Concentration (Cmax) of LAM-002ALAM-002A Continuous Monotherapy - 50 mg BIDApilimod - Day 1117Standard Deviation 69.6ng/mL
Peak Plasma Concentration (Cmax) of LAM-002ALAM-002A Continuous Monotherapy - 75 mg TIDApilimod - Day 1158Standard Deviation 61.6ng/mL
Peak Plasma Concentration (Cmax) of LAM-002ALAM-002A Continuous Monotherapy - 100 mg BIDApilimod - Day 1263Standard Deviation 168ng/mL
Peak Plasma Concentration (Cmax) of LAM-002ALAM-002A Continuous Monotherapy - 125 mg BIDApilimod - Day 1207Standard Deviation 82.4ng/mL
Peak Plasma Concentration (Cmax) of LAM-002ALAM-002A Continuous Monotherapy - 150 mg BIDApilimod - Day 1243Standard Deviation 76.1ng/mL
Peak Plasma Concentration (Cmax) of LAM-002ALAM-002A Intermittent Monotherapy - 150 mgApilimod - Day 1280Standard Deviation 135ng/mL
Peak Plasma Concentration (Cmax) of LAM-002ALAM-002A Continuous Monotherapy - 50 mg BIDApilimod - Day 8140Standard Deviation 95.1ng/mL
Peak Plasma Concentration (Cmax) of LAM-002ALAM-002A Continuous Monotherapy - 75 mg TIDApilimod - Day 8339Standard Deviation 215ng/mL
Peak Plasma Concentration (Cmax) of LAM-002ALAM-002A Continuous Monotherapy - 100 mg BIDApilimod - Day 8331Standard Deviation 273ng/mL
Peak Plasma Concentration (Cmax) of LAM-002ALAM-002A Continuous Monotherapy - 125 mg BIDApilimod - Day 8331Standard Deviation 287ng/mL
Peak Plasma Concentration (Cmax) of LAM-002ALAM-002A Continuous Monotherapy - 150 mg BIDApilimod - Day 8369Standard Deviation 90.5ng/mL
Peak Plasma Concentration (Cmax) of LAM-002ALAM-002A Intermittent Monotherapy - 150 mgApilimod - Day 8108ng/mL
Peak Plasma Concentration (Cmax) of LAM-002ALAM-002A Continuous Monotherapy - 50 mg BIDSTA-5908 - Day 1112Standard Deviation 85.0ng/mL
Peak Plasma Concentration (Cmax) of LAM-002ALAM-002A Continuous Monotherapy - 75 mg TIDSTA-5908 - Day 1114Standard Deviation 71.6ng/mL
Peak Plasma Concentration (Cmax) of LAM-002ALAM-002A Continuous Monotherapy - 100 mg BIDSTA-5908 - Day 1215Standard Deviation 88.6ng/mL
Peak Plasma Concentration (Cmax) of LAM-002ALAM-002A Continuous Monotherapy - 125 mg BIDSTA-5908 - Day 1144Standard Deviation 92.5ng/mL
Peak Plasma Concentration (Cmax) of LAM-002ALAM-002A Continuous Monotherapy - 150 mg BIDSTA-5908 - Day 1196Standard Deviation 142ng/mL
Peak Plasma Concentration (Cmax) of LAM-002ALAM-002A Intermittent Monotherapy - 150 mgSTA-5908 - Day 1207Standard Deviation 135ng/mL
Peak Plasma Concentration (Cmax) of LAM-002ALAM-002A Continuous Monotherapy - 50 mg BIDSTA-5908 - Day 8103Standard Deviation 43.7ng/mL

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02594384/results

API referenceFor AI assistants